The deal includes MiroBio’s proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists.
MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) which is currently in phase 1 clinical trials, with the first patient dosed in early August 2022. The antibody targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.
